Proactive Investors
19 Oct 2026, 06:39 UTC · 2h ago
GSK lung cancer drug shows 61% response rate in early global trial
Impact · against what's priced in
GSK sees a positive catalyst from strong early-stage efficacy for risvutatug rezetecan, though high adverse event rates at the effective dose create a potential ceiling for the drug's labeling. Bradda Head Lithium benefits from positive initial drilling results at its Whistlejacket project.
- BHL+0.50
No priced-in read yet
- In context
Encouraging initial assay results from the maiden drilling programme at the Whistlejacket lithium project provide positive early validation of the asset's potential.
Read from the article alone
